Abstract: This disclosure relates to compositions for use in managing respiratory distress and related disorders. In certain embodiments, the disclosure relates to methods of treating or preventing respiratory distress comprising administering an effective amount of a pharmaceutical composition comprising peptides or agents disclosed herein to a subject in need thereof. In certain embodiments, the peptides or agents decrease the concentration of claudin-5 in cells and tissues of the lungs.

Abstract: Provided is a peptide for preventing or treating inflammatory diseases and a use thereof. According to a novel dimeric peptide according to the present invention, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances and will be expected to be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.

Abstract: Provided is a novel peptide for preventing or treating inflammatory diseases and a use thereof. According to the novel dimeric or trimeric peptide, it is possible to not only exhibit an excellent therapeutic effect through anti-inflammatory action but also have a very small-sized peptide, thereby minimizing side effects due to the administration of external substances. Therefore, it is expected that the peptide can be used as an active substance that can replace existing therapeutic agents for inflammatory diseases.

Abstract: Compositions are disclosed that include D-amino acid peptides and that are capable of specifically binding to at least one autoantibody against a G-protein coupled receptor. The autoantibody is produced in a patient having or being predisposed to a disease, condition, or disorder, and the autoantibody is capable of binding to a specific epitope of the G-protein coupled receptor. Methods of production and use of said compositions are also disclosed.

Abstract: During the process of coagulation, prothrombin is activated to ?-thrombin by prothrombinase. Key residues in the structure of prothrombin allow for modulation of the activation of prothrombin. In certain embodiments, a recombinant prothrombin with at least one point mutation or deletion is provided.

Abstract: The present application relates to methods of treating HIV-associated nephropathy (HIVAN) and/or focal segmental glomerulosclerosis (FSGS) using endothelin-1 (ET-1) antagonists. The application further relates to a composition for the treatment of HIVAN and/or FSGS. A kit for detecting the presence of ET-1 or ET-1-associated biomarker in a biological sample is also disclosed.

Abstract: A method for preparing a cyclopeptide, which includes the following steps: (A) providing compounds represented by the following formulas (II-1) or (II?-1) and (II-2); (B) performing a reaction between the compounds of formulas (II-1) or (II?-1) and (II-2), to obtain a compound represented by the following formula (II-3) and (II?-3), respectively; (C) performing a reaction between the compound of formula (II-3) or (II?-3) and a compound represented by the following formula (II-4) or (II?-4), respectively, is performed, to obtain a compound represented by the following formula (II-5), and (II?-5), respectively; (D) performing a cyclization reaction of the compound of formula (II-5) or (II?-5) with a catalyst of formula (III), to obtain a compound represented by the following formula (I) or (I?), respectively. The formulas (I), (I?), (II-1) to (II-5), (II?-1) to (II?-5) and (III) are shown in the specification.

Abstract: Described herein is a mono-end PEGyated functional upstream domain (FUD), pharmaceutical compositions, and its use to inhibit fibrosis such as organ fibrosis, idiopathic pulmonary fibrosis and fibrosis associated with cancer. Also included are methods of probing for injured or repairing tissue in an individual in need thereof using the mono-end PEGyated-FUD.

Abstract: The disclosure of the present application relates to a secretory deleted split hand/split foot 1 (sDSS1) protein, the amino acid sequence thereof, the nucleic acid sequence thereof, and the applications of the same. The sDSS1 protein is a secretory protein from higher primate, and can be detected in human serum and cerebral spinal fluid (CSF). The sDSS1 protein can form conjugate with oxidized protein under nonenzymatic condition or with amyloid-beta (A?) polypeptide to reduce formation of A? oligomer. The addition of sDSS1 protein to culture medium can shield the cytotoxicity induced by oxidized protein, A? oligomer, amylin oligomer and glycosylated protein, so as to protect the cells against these toxoproteins. The sDSS1 protein can prolong survival time of senescence-accelerated mice significantly.

Abstract: The present invention relates to compositions which may comprise a non-naturally occurring or engineered artificial transcription factor, wherein the transcription factor may comprise a sequence specific DNA binding domain, a sliding domain, and one or more linkers, wherein the DNA binding domain and the sliding domain are operably connected by the one or more linkers, and uses thereof. Methods involving the use of a non-naturally occurring or engineered artificial transcription factors and pharmaceutical compositions, methods for treating cancer, a degenerative disease, a genetic disease or an infectious disease as well as diagnostic methods are also contemplated by the present invention.

Abstract: A cosmetic composition is provided, the composition comprising a safe and effective amount of a skin care active with A log P less than ?2.0, a safe and effective amount of a fatty alcohol; and a safe and effective amount of a glyceryl ester. The combination of fatty alcohol and glyceryl esters surprisingly enhances penetration of skin care actives with low A log P values into skin.

Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.

Abstract: In various aspects, embodiments of the present invention are directed to a series of multivalent dendrons containing a bioactive peptide domain and surface-binding catechol domains. In some embodiments, these multivalent dendrons were obtained through solid phase synthesis and have a strong binding affinity to metal oxide surfaces such as, TiO2, ZrO2, CeO2, and Fe3O4, SiO2, as well as other inorganic surfaces such as hydroxyapatite, silver, fluorapatite, calcium carbonate and gold. These catechol-bearing dendrons provide a fast and efficient method to functionalize a wide range of inorganic materials with bioactive peptides and have the potential to be used in coating orthopaedic implants and fixation devices.

Abstract: A cyclopeptide is disclosed, which is represented by the following formula (I) or (I?): wherein R1 is defined in the specification. In addition, a pharmaceutical or cosmetic composition comprising the same and a method for preparing the same are also disclosed.

Abstract: Methods, reagents, and kits for the reversible immobilization of glycoproteins to a solid support, the release and capture of a glycan portion of the glycoprotein, and the subsequent release and capture of the polypeptide portion of the glycoprotein are provided. The disclosure also provides suitable solid support materials, surface chemistries, and devices for use in the disclosed methods. The methods, reagents, kits, and devices provided herein are useful for the analysis of protein glycosylation, for example, in a diagnostic context, in the context of proteoglycomics, and in the context of producing glycosylated proteins for therapeutic purposes.

Abstract: This disclosure relates to compositions for use in managing respiratory distress and related disorders. In certain embodiments, the disclosure relates to methods of treating or preventing respiratory distress comprising administering an effective amount of a pharmaceutical composition comprising peptides or agents disclosed herein to a subject in need thereof. In certain embodiments, the peptides or agents decrease the concentration of claudin-5 in cells and tissues of the lungs.

Abstract: Anti-microbial peptides and methods of use are provided.

Abstract: Two peptides that can selectively bind to SEVI and block the enhanced infectivity that results from the interaction of SEVI with HIV. The two peptides comprise the amino acid sequences FEEIVQEIEDFLENLV (SEQ. ID NO: 1) and GIGAVLEVLTTGLPALISWIEEEEQQ (SEQ. ID. NO: 2). The peptides may be administered topically, either alone or in combination with other prophylactics, agents, etc.

Abstract: We describe an ELABELA polypeptide comprising a sequence CXXXRCXXXHSRVPFP (SEQ ID NO: 1), in which X signifies an amino acid residue, such as a sequence selected from the group consisting of: SEQ ID NO: 2 to SEQ ID NO: 18, preferably CLQRRCMPLHSRVPFP (SEQ ID NO: 2), or a fragment, homologue, variant or derivative thereof, which polypeptide is capable of maintaining self-renewal and/or pluripotency of a stem cell.

Abstract: Immobilizable antimicrobial compounds incorporating antimicrobial and/or antifouling components, as can be adhered to various device structures and components.